A detailed history of Mn Services Vermogensbeheer B.V. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Mn Services Vermogensbeheer B.V. holds 492,755 shares of GILD stock, worth $43.4 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
492,755
Previous 503,855 2.2%
Holding current value
$43.4 Million
Previous $36.9 Million 8.4%
% of portfolio
0.24%
Previous 0.27%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$63.15 - $72.88 $700,965 - $808,968
-11,100 Reduced 2.2%
492,755 $33.8 Million
Q1 2024

Apr 29, 2024

SELL
$71.58 - $87.29 $6.28 Million - $7.66 Million
-87,800 Reduced 14.84%
503,855 $36.9 Million
Q4 2023

Jan 29, 2024

SELL
$73.27 - $83.09 $1.38 Million - $1.57 Million
-18,900 Reduced 3.1%
591,655 $47.9 Million
Q3 2023

Oct 25, 2023

BUY
$73.94 - $80.67 $805,946 - $879,303
10,900 Added 1.82%
610,555 $45.8 Million
Q2 2023

Aug 09, 2023

SELL
$76.01 - $86.7 $1.9 Million - $2.17 Million
-25,000 Reduced 4.0%
599,655 $46.2 Million
Q1 2023

Apr 26, 2023

BUY
$77.31 - $88.08 $1.46 Million - $1.66 Million
18,900 Added 3.12%
624,655 $51.8 Million
Q4 2022

Feb 03, 2023

SELL
$62.32 - $89.47 $5.68 Million - $8.16 Million
-91,200 Reduced 13.09%
605,755 $52 Million
Q3 2022

Nov 01, 2022

SELL
$59.54 - $68.01 $2.39 Million - $2.73 Million
-40,100 Reduced 5.44%
696,955 $43 Million
Q2 2022

Aug 03, 2022

SELL
$57.72 - $65.01 $9.5 Million - $10.7 Million
-164,600 Reduced 18.26%
737,055 $45.6 Million
Q1 2022

May 10, 2022

SELL
$57.92 - $72.58 $3.33 Million - $4.17 Million
-57,500 Reduced 5.99%
901,655 $53.6 Million
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $1.15 Million - $1.31 Million
17,800 Added 1.89%
959,155 $69.6 Million
Q3 2021

Nov 03, 2021

BUY
$67.69 - $73.03 $1.35 Million - $1.45 Million
19,900 Added 2.16%
941,355 $65.8 Million
Q2 2021

Aug 05, 2021

SELL
$63.47 - $69.35 $12 Million - $13.2 Million
-189,800 Reduced 17.08%
921,455 $53.5 Million
Q4 2020

Feb 09, 2021

BUY
$56.65 - $64.55 $725,120 - $826,240
12,800 Added 1.17%
1,111,255 $64.7 Million
Q3 2020

Nov 04, 2020

BUY
$62.1 - $78.08 $1.34 Million - $1.69 Million
21,600 Added 2.01%
1,098,455 $69.4 Million
Q2 2020

Jul 23, 2020

SELL
$72.34 - $84.0 $1.14 Million - $1.33 Million
-15,800 Reduced 1.45%
1,076,855 $82.9 Million
Q1 2020

May 12, 2020

SELL
$62.63 - $80.22 $4.3 Million - $5.51 Million
-68,700 Reduced 5.92%
1,092,655 $81.7 Million
Q4 2019

Feb 12, 2020

BUY
$61.62 - $67.78 $2.26 Million - $2.49 Million
36,700 Added 3.26%
1,161,355 $75.5 Million
Q3 2019

Nov 12, 2019

BUY
$62.51 - $69.0 $29.5 Million - $32.5 Million
471,725 Added 72.25%
1,124,655 $71.3 Million
Q2 2019

Jul 25, 2019

SELL
$61.87 - $69.38 $4.21 Million - $4.72 Million
-68,000 Reduced 9.43%
652,930 $44.1 Million
Q1 2019

May 06, 2019

BUY
$62.53 - $70.05 $406,445 - $455,325
6,500 Added 0.91%
720,930 $46.9 Million
Q4 2018

Feb 12, 2019

BUY
$60.54 - $79.0 $30.6 Million - $40 Million
505,855 Added 242.53%
714,430 $39.1 Million
Q3 2018

Nov 02, 2018

SELL
$71.28 - $78.92 $49,896 - $55,244
-700 Reduced 0.33%
208,575 $16.1 Million
Q2 2018

Aug 13, 2018

BUY
$64.88 - $75.68 $240,055 - $280,016
3,700 Added 1.8%
209,275 $14.8 Million
Q1 2018

May 11, 2018

BUY
$72.84 - $88.8 $167,532 - $204,240
2,300 Added 1.13%
205,575 $15.5 Million
Q4 2017

Feb 02, 2018

SELL
$71.15 - $83.52 $868,030 - $1.02 Million
-12,200 Reduced 5.66%
203,275 $12.1 Million
Q3 2017

Nov 01, 2017

BUY
$72.11 - $85.47 $15.5 Million - $18.4 Million
215,475
215,475 $17.5 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Mn Services Vermogensbeheer B.V. Portfolio

Follow Mn Services Vermogensbeheer B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mn Services Vermogensbeheer B.V., based on Form 13F filings with the SEC.

News

Stay updated on Mn Services Vermogensbeheer B.V. with notifications on news.